Evidence map›Paper›PMID 37955026›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2023

The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD Readmissions.

Constantinos Kallis, Amit Kaura, Nathan A Samuel, Abdulrahim Mulla, Ben Glampson, Kevin O'Gallagher, Jim Davies, Dimitri Papadimitriou, Kerrie J Woods, Anoop D Shah and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 12 institutions in 1 country.

Constantinos KallisNational Heart and Lung Institute, Imperial College London, London, UK.
Amit KauraNational Heart and Lung Institute, Imperial College London, London, UK.
Nathan A SamuelNIHR Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Abdulrahim MullaNIHR Imperial Biomedical Research Centre, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Ben GlampsonNIHR Imperial Biomedical Research Centre, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Kevin O'GallagherNIHR King's Biomedical Research Centre, King's College London and King's College Hospital NHS Foundation Trust, London, UK.
Jim DaviesNIHR Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Dimitri PapadimitriouNIHR Imperial Biomedical Research Centre, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Kerrie J WoodsNIHR Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Anoop D ShahNIHR University College London Biomedical Research Centre, University College London and University College London Hospitals NHS Foundation Trust, London, UK.
Bryan WilliamsNIHR University College London Biomedical Research Centre, University College London and University College London Hospitals NHS Foundation Trust, London, UK.
Folkert W AsselbergsNIHR University College London Biomedical Research Centre, University College London and University College London Hospitals NHS Foundation Trust, London, UK.
Erik K MayerNIHR Imperial Biomedical Research Centre, Imperial College London and Imperial College Healthcare NHS Trust, London, UK.
Richard W LeeNational Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0001-8368-3406
Christopher HerbertNIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK.
Stuart W GrantNIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust and the University of Manchester, Manchester, UK.
Nick CurzenNIHR Southampton Clinical Research Facility and Biomedical Research Centre, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Iain B SquireNIHR Leicester Biomedical Research Centre, Glenfield Hospital, and Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Thomas JohnsonNIHR Bristol Biomedical Research Centre, University of Bristol and University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Ajay M ShahNIHR Guys & St Thomas' Hospital Clinical Research Facility, King's College Hospital, and King's College London British Heart Foundation Centre of Excellence, London, UK.
Divaka PereraNIHR King's Biomedical Research Centre, King's College London and King's College Hospital NHS Foundation Trust, London, UK.
Rajesh K KharbandaNIHR Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Riyaz S PatelNIHR University College London Biomedical Research Centre, University College London and University College London Hospitals NHS Foundation Trust, London, UK.
Keith M ChannonNIHR Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Jamil MayetNational Heart and Lung Institute, Imperial College London, London, UK.
Jennifer K QuintNational Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-0149-4869
Imperial College Healthcare NHS Trust · GBUniversity of Oxford · GBUCL Biomedical Research Centre · GBKing's College London · GBBritish Heart Foundation · GBInstitute of Cancer Research · GBManchester University NHS Foundation Trust · GBSt Thomas' Hospital · GBUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Leeds · GBUniversity of Leicester · GB

Funding

British Heart Foundation CH/16/1/32013British Heart Foundation FS/20/18/34972British Heart Foundation FS/CRA/22/23036British Heart Foundation SP/17/16/33519
6 · The paper itself

Abstract

Background: No single biomarker currently risk stratifies chronic obstructive pulmonary disease (COPD) patients at the time of an exacerbation, though previous studies have suggested that patients with elevated troponin at exacerbation have worse outcomes. This study evaluated the relationship between peak cardiac troponin and subsequent major adverse cardiac events (MACE) including all-cause mortality and COPD hospital readmission, among patients admitted with COPD exacerbation. Methods: Data from five cross-regional hospitals in England were analysed using the National Institute of Health Research Health Informatics Collaborative (NIHR-HIC) acute coronary syndrome database (2008-2017). People hospitalised with a COPD exacerbation were included, and peak troponin levels were standardised relative to the 99th percentile (upper limit of normal). We used Cox Proportional Hazard models adjusting for age, sex, laboratory results and clinical risk factors, and implemented logarithmic transformation (base-10 logarithm). The primary outcome was risk of MACE within 90 days from peak troponin measurement. Secondary outcome was risk of COPD readmission within 90 days from peak troponin measurement. Results: There were 2487 patients included. Of these, 377 (15.2%) patients had a MACE event and 203 (8.2%) were readmitted within 90 days from peak troponin measurement. A total of 1107 (44.5%) patients had an elevated troponin level. Of 1107 patients with elevated troponin at exacerbation, 256 (22.8%) had a MACE event and 101 (9.0%) a COPD readmission within 90 days from peak troponin measurement. Patients with troponin above the upper limit of normal had a higher risk of MACE (adjusted HR 2.20, 95% CI 1.75-2.77) and COPD hospital readmission (adjusted HR 1.37, 95% CI 1.02-1.83) when compared with patients without elevated troponin. Conclusion: An elevated troponin level at the time of COPD exacerbation may be a useful tool for predicting MACE in COPD patients. The relationship between degree of troponin elevation and risk of future events is complex and requires further investigation.

Indexed as

Cardiovascular DiseasesPulmonary Disease, Chronic ObstructiveHospitalizationHumansPatient ReadmissionTroponinTroponinCOPDCVDexacerbation

Identifiers

PMID37955026
PMCPMC10637362
OpenAlexW4388417145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.